| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 浙江奥翔药业股份有限公司成立于2010年4月，2017年5月9日在上海证券交易所挂牌上市，股票代码603229。 公司位于浙江省台州湾经济技术开发区，为国家级高新技术企业。目前，公司建有国家级博士后工作站，浙江省重点企业研究院、省企业技术中心、省研发中心等平台。现有员工1000余人，拥有一支由博士、硕士等组成的300多人的研究开发和分析团队。 公司主要从事药物制剂、特色原料药、医药关键中间体的研发、生产、销售，以及为客户提供定制加工和研发业务；产品主要出口欧、美、日、韩等国家和地区。2022年公司营业收入同比增长34.2%，净利润同比增长61.29%。 公司的产品主要分为肝病类、呼吸系统类、心脑血管类、高端氟产品类、前列腺素类、抗菌类、痛风类、抗肿瘤类共八大类，所开发产品手性结构多、研发难度大、技术壁垒高、生产工艺独特，公司高度重视技术创新与研发，近三年，研发投入占营业收入比重均超过10%。 公司专注于健康产业，始终秉持“品质+创新”的核心理念，以“服务健康，共创未来”为企业宗旨，按照我国医药工业“十四五”行业规划要求和国家创新发展战略，以“人才、共赢”为发展的指导思想，打造具有新药创制能力且仿制药技术国际一流的研发创新体系，同时不断扩大销售网络的覆盖面，积极开拓美国、日本、欧洲等高端规范市场，力争在未来成为具有全球竞争力的特色制药企业。 | ||||||||||||||||||||||||
| Main Business | 特色原料药及医药中间体的研发、生产和销售，以及为客户提供定制生产和研发业务。 | ||||||||||||||||||||||||
| Legal Representative | 郑志国 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 应晓晨 | ||||||||||||||||||||||||
| Solicitors | 北京海润天睿律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0576-85589367 | ||||||||||||||||||||||||
| Fax No | 0576-85589367 | ||||||||||||||||||||||||
| Website | www.ausunpharm.com | ||||||||||||||||||||||||
| board@ausunpharm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 09/05/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.430 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.129 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.611 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 6.875B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |